calciol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
calciol — decreases interleukin-6 concentration
Evidence strength: very limited.Findingreplicated ×1“Additionally, we observed a significant reduction in high-sensitivity C-reactive protein levels after 3 months (median: 0.62 [0.05 to 29.6] mg/L vs. 0.32 [0.02 to 3.13] mg/L; P = .02) and after 6 months (median: 0.62 [0.05 to 29.6] mg/L vs. 0.50 [0.02 to 5.66] mg/L; P = .04) of cholecalciferol supplementation, as well as a significant reduction in interleukin-6 levels (median: 6.44 pg/mL vs. 3.83 pg/mL; P = .018) after 6 months of supplementation.”
Quoted verbatim from Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism.. - Study
- cohort
- Dose
- oral cholecalciferol once weekly, 50,000 IU for the first 12 weeks then 20,000 IU for the last 12 weeks
- Population
- Haemodialysis patients with hypovitaminosis D (25(OH)D <30 ng/mL) and iPTH <300 pg/mL, not receiving vitamin D therapy; single-group before-and-after comparison with baseline; IL-6 at 6 months
Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism.2012PMID:2190820310.1053/j.jrn.2011.07.001Permalink
To cite this finding: https://catalystproject.ai/e/01M5RTE5196ACMBR9KYRZK0DEP